<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31867846</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1755-5949</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>CNS neuroscience &amp; therapeutics</Title><ISOAbbreviation>CNS Neurosci Ther</ISOAbbreviation></Journal><ArticleTitle>Neuro-Cells therapy improves motor outcomes and suppresses inflammation during experimental syndrome of amyotrophic lateral sclerosis in mice.</ArticleTitle><Pagination><StartPage>504</StartPage><EndPage>517</EndPage><MedlinePgn>504-517</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cns.13280</ELocationID><Abstract><AbstractText Label="AIMS">Mutations in DNA/RNA-binding factor (fused-in-sarcoma) FUS and superoxide dismutase-1 (SOD-1) cause amyotrophic lateral sclerosis (ALS). They were reproduced in SOD-1-G93A (SOD-1) and new FUS[1-359]-transgenic (FUS-tg) mice, where inflammation contributes to disease progression. The effects of standard disease therapy and anti-inflammatory treatments were investigated using these mutants.</AbstractText><AbstractText Label="METHODS">FUS-tg mice or controls received either vehicle, or standard ALS treatment riluzole (8&#xa0;mg/kg/day), or anti-inflammatory drug a selective blocker of cyclooxygenase-2 celecoxib (30&#xa0;mg/kg/day) for six weeks, or a single intracerebroventricular (i.c.v.) infusion of Neuro-Cells (a preparation of 1.39&#xa0;&#xd7;&#xa0;10<sup>6</sup> mesenchymal and hemopoietic human stem cells, containing 5&#xa0;&#xd7;&#xa0;10<sup>5</sup> of CD34<sup>+</sup> cells), which showed anti-inflammatory properties. SOD-1 mice received i.c.v.-administration of Neuro-Cells or vehicle.</AbstractText><AbstractText Label="RESULTS">All FUS-tg-treated animals displayed less marked reductions in weight gain, food/water intake, and motor deficits than FUS-tg-vehicle-treated mice. Neuro-Cell-treated mutants had reduced muscle atrophy and lumbar motor neuron degeneration. This group but not celecoxib-FUS-tg-treated mice had ameliorated motor performance and lumbar expression of microglial activation marker, ionized calcium-binding adapter molecule-1 (Iba-1), and glycogen-synthase-kinase-3&#xdf; (GSK-3&#xdf;). The Neuro-Cells-treated-SOD-1 mice showed better motor functions than vehicle-treated-SOD-1 group.</AbstractText><AbstractText Label="CONCLUSION">The neuropathology in FUS-tg mice is sensitive to standard ALS treatments and Neuro-Cells infusion. The latter improves motor outcomes in two ALS models possibly by suppressing microglial activation.</AbstractText><CopyrightInformation>&#xa9; 2019 The Authors. CNS Neuroscience &amp; Therapeutics published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Munter</LastName><ForeName>Johannes P J M</ForeName><Initials>JPJM</Initials><Identifier Source="ORCID">0000-0001-7583-1464</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shafarevich</LastName><ForeName>Igor</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-0350-8013</Identifier><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liundup</LastName><ForeName>Alexei</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0102-5491</Identifier><AffiliationInfo><Affiliation>Institute of Regenerative Medicine, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavlov</LastName><ForeName>Dmitrii</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-8584-4901</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Cognitive Dysfunctions, Institute of General Pathology and Pathophysiology, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolters</LastName><ForeName>Erik Ch</ForeName><Initials>EC</Initials><Identifier Source="ORCID">0000-0003-4411-6892</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorlova</LastName><ForeName>Anna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9345-7880</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veniaminova</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3477-7099</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umriukhin</LastName><ForeName>Aleksei</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1637-4245</Identifier><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalueff</LastName><ForeName>Allan</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7525-1950</Identifier><AffiliationInfo><Affiliation>Faculty of Biology, Ural Federal University, Ekaterinburg, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmacy, Southwest University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svistunov</LastName><ForeName>Andrei</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2618-9959</Identifier><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Regenerative Medicine, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Boris W</ForeName><Initials>BW</Initials><Identifier Source="ORCID">0000-0002-8153-7103</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, University Medical Center (MUCM), Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lesch</LastName><ForeName>Klaus-Peter</ForeName><Initials>KP</Initials><Identifier Source="ORCID">0000-0001-8348-153X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Molecular Psychiatry, Center of Mental Health, University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strekalova</LastName><ForeName>Tatyana</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-9937-5600</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Psychiatric Neurobiology, Institute of Molecular Medicine and Department of Normal Physiology, Sechenov First Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Cognitive Dysfunctions, Institute of General Pathology and Pathophysiology, Moscow, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Molecular Psychiatry, Center of Mental Health, University of W&#xfc;rzburg, W&#xfc;rzburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>CNS Neurosci Ther</MedlineTA><NlmUniqueID>101473265</NlmUniqueID><ISSNLinking>1755-5930</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C109415">SOD1 G93A protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>CNS Neurosci Ther. 2020 May;26(5):502-503</RefSource><PMID Version="1">32181601</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018380" MajorTopicYN="N">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007276" MajorTopicYN="N">Injections, Intraventricular</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019957" MajorTopicYN="N">Motor Skills Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">fused in sarcoma (FUS) protein</Keyword><Keyword MajorTopicYN="N">glycogen-synthase kinase-3&#xdf; (GSK-3&#xdf;)</Keyword><Keyword MajorTopicYN="N">microglia activation</Keyword><Keyword MajorTopicYN="N">mouse</Keyword><Keyword MajorTopicYN="N">stem cell therapy</Keyword><Keyword MajorTopicYN="N">superoxide dismutase-1 (SOD-1) G93A mice</Keyword></KeywordList><CoiStatement>HdM and EW are CEOs of Neuroplast BV, Maastricht, Netherlands, and have filed a patent describing the Neuro&#x2010;Cells preparation that was used as one of three treatments in this study. The application number of the patent filing is 15/525328. TS is a consultant at Neuroplast BV.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31867846</ArticleId><ArticleId IdType="pmc">PMC7163689</ArticleId><ArticleId IdType="doi">10.1111/cns.13280</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al&#x2010;Chalabi A, Hardiman O, Kiernan MC, Chio A, Rix&#x2010;Brooks B, van den Berg LH. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016;15:1182&#x2010;1194.</Citation><ArticleIdList><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair IP, Williams KL, Warraich ST, et al. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry. 2010;81:639&#x2010;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">19965854</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, M&#xfc;ller K, Zondler L, et al. Serum microRNAs in sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2015;36(2660):e15&#x2010;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26142125</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz C. Mouse models of ALS: Past, present and future. Brain Res. 2018;1693:1&#x2010;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">29577886</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatelli M, Moncada A, Conte A, et al. Mutations in the 3' untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis. Hum Mol Genet. 2013;22:4748&#x2010;4755.</Citation><ArticleIdList><ArticleId IdType="pubmed">23847048</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrone L, Drexler HCA, Wang J, et al. FUS pathology in ALS is linked to alterations in multiple ALS&#x2010;associated proteins and rescued by drugs stimulating autophagy. Acta Neuropathol. 2019;138:67&#x2010;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570784</ArticleId><ArticleId IdType="pubmed">30937520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez&#x2010;Erauskin J, Tadokoro T, Baughn MW, et al. ALS/FTD&#x2010;linked mutation in FUS suppresses intra&#x2010;axonal protein synthesis and drives disease without nuclear loss&#x2010;of&#x2010;function of FUS. Neuron. 2018;100(4):816&#x2010;830.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6277851</ArticleId><ArticleId IdType="pubmed">30344044</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox AH, Lamond AI. Paraspeckles. Cold Spring Harb Perspect Biol. 2010;2:a000687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890200</ArticleId><ArticleId IdType="pubmed">20573717</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelkovnikova TA, Peters OM, Deykin AV, et al. Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice. J Biol Chem. 2013;288:25266&#x2010;25274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3757190</ArticleId><ArticleId IdType="pubmed">23867462</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelkovnikova TA, Kukharsky MS, An H, et al. Protective paraspeckle hyper&#x2010;assembly downstream of TDP&#x2010;43 loss of function in amyotrophic lateral sclerosis. Mol Neurodegener. 2018;13:30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5984788</ArticleId><ArticleId IdType="pubmed">29859124</ArticleId></ArticleIdList></Reference><Reference><Citation>An H, Skelt L, Notaro A, et al. ALS&#x2010;linked FUS mutations confer loss and gain of function in the nucleus by promoting excessive formation of dysfunctional paraspeckles. Acta Neuropathol Commun. 2019;7:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6330737</ArticleId><ArticleId IdType="pubmed">30642400</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang&#x2010;Fu N, Cheng JS, Wang Y, Li ZW, Wang SH. Neat1 regulates oxidized low&#x2010;density lipoprotein&#x2010;induced inflammation and lipid uptake in macrophages via paraspeckle formation. Mol Med Rep. 2018;17:3092&#x2010;3098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5783531</ArticleId><ArticleId IdType="pubmed">29257236</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Cao L, Zhou R, Yang X, Wu M. The lncRNA Neat1 promotes activation of inflammasomes in macrophages. Nat Commun. 2019;10:1495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6445148</ArticleId><ArticleId IdType="pubmed">30940803</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello G, Spampinato AG, Cavallaro S. Neuroinflammation and ALS: transcriptomic insights into molecular disease mechanisms and therapeutic targets. Mediators Inflamm. 2017;2017:7070469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610842</ArticleId><ArticleId IdType="pubmed">29081603</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra PS, Vijayalakshmi K, Nalini A, et al. Etiogenic factors present in the cerebrospinal fluid from amyotrophic lateral sclerosis patients induce predominantly pro&#x2010;inflammatory responses in microglia. J Neuroinflammation. 2017;14:251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5732516</ArticleId><ArticleId IdType="pubmed">29246232</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisafulli SG, Brajkovic S, Cipolat MS, Parente V, Corti S. Therapeutic strategies under development targeting inflammatory mechanisms in amyotrophic lateral sclerosis. Mol Neurobiol. 2018;55:2789&#x2010;2813.</Citation><ArticleIdList><ArticleId IdType="pubmed">28455693</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Cao C, Qin XY, et al. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta&#x2010;analysis study. Sci Rep. 2017;7:9094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Shruthi S, Sumitha R, Varghese AM, et al. Brain&#x2010;derived neurotrophic factor facilitates functional recovery from ALS&#x2010;cerebral spinal fluid&#x2010;induced neurodegenerative changes in the NSC&#x2010;34 motor neuron cell line. Neurodegener. 2017;17:44&#x2010;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">27617773</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, Moglia C, Balma M, Chi&#xf2; A. Involvement of immune response in the pathogenesis of amyotrophic lateral sclerosis: a therapeutic opportunity? CNS Neurol Disord Drug Targets. 2010;9:325&#x2010;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">20406178</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6:1045&#x2010;1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">17980667</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins M, Bowser R. Molecular and Cellular Therapies for Motor Neuron Diseases. 2017;61&#x2010;99. Amsterdam: Academic Press.</Citation></Reference><Reference><Citation>de Munter JP, Wolters E. Autologous adult stem cells in ischemic and traumatic CNS disorders. J Neural Transm. 2013;120:91&#x2010;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">22842676</ArticleId></ArticleIdList></Reference><Reference><Citation>de Munter JP, Beugels J, Janssen L, et al. Standardized human bone marrow&#x2010;derived Stem Cells Infusion Improves Survival and Recovery in a rat model of Spinal Cord Injury. J Neurol Sci. 2019;402:16&#x2010;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">31100652</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Bendotti C, Blaugrund E, et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler. 2010;11:38&#x2010;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">20184514</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2010;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Lysikova EA, Funikov S, Rezvykh AP, et al. Low level of expression of C&#x2010;terminally truncated human FUS causes extensive changes in spinal cord transcriptome of asymptomatic transgenic mice. BioRvix Neurosci. 2019. 10.1101/689414</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/689414</ArticleId><ArticleId IdType="pubmed">32157564</ArticleId></ArticleIdList></Reference><Reference><Citation>Lysikova EA, Kukharsky MS, Chaprov KD, et al. Behavioural impairments in mice of a novel FUS transgenic line recapitulate features of frontotemporal lobar degeneration. Genes Brain Behav. 2019;22:12607.</Citation><ArticleIdList><ArticleId IdType="pubmed">31437340</ArticleId></ArticleIdList></Reference><Reference><Citation>Babaevskaya D, de Munter J, Trofimov A, Costa&#x2010;Nunes J, Pavlov D, Veniaminova E, Oplatchikova M, Gorlova A, Lesch KP, Wolters E, Anthony D, Strekalova T.Neuroinflammation in a mouse model of amyotrophic lateral sclerosis with FUS gene mutation and effects of standard and new therapies. https://www.nwg&#x2010;goettingen.de/2019/upload/file/Proceedings&#x2010;NWG&#x2010;2019.pdf, 2019.</Citation></Reference><Reference><Citation>Fitzsimmons REB, Mazurek MS, Soos A, Simmons CA. Mesenchymal stromal/stem cells in regenerative medicine and tissue engineering. Stem Cell Int. 2018;2018:8031718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6120267</ArticleId><ArticleId IdType="pubmed">30210552</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrzejewska A, Jablonska A, Seta M, et al. Labeling of human mesenchymal stem cells with different classes of vital stains: robustness and toxicity. Stem Cell Res Ther. 2019;10:187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6593614</ArticleId><ArticleId IdType="pubmed">31238982</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SS, Yoo SW, Park TS, et al. Neural induction with neurogenin1 increases the therapeutic effects of mesenchymal stem cells in the ischemic brain. Stem Cells. 2008;26:2217&#x2010;2228.</Citation><ArticleIdList><ArticleId IdType="pubmed">18617687</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurjonsson OE, Perreault MC, Egeland T, Glover JC. Adult human hematopoietic stem cells produce neurons efficiently in the regenerating chicken embryo spinal cord. Proc Natl Acad Sci USA. 2005;102:5227&#x2010;5232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556004</ArticleId><ArticleId IdType="pubmed">15790679</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofstetter CP, Schwarz EJ, Hess D, et al. Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. Proc Natl Acad Sci USA. 2002;99:2199&#x2010;2204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122342</ArticleId><ArticleId IdType="pubmed">11854516</ArticleId></ArticleIdList></Reference><Reference><Citation>Samdani AF, Paul C, Betz RR, Fischer I, Neuhuber B. Transplantation of human marrow stromal cells and mono&#x2010;nuclear bone marrow cells into the injured spinal cord: a comparative study. Spine. 1976;2009(34):2605&#x2010;2612.</Citation><ArticleIdList><ArticleId IdType="pubmed">19881401</ArticleId></ArticleIdList></Reference><Reference><Citation>Uccelli A, Milanese M, Principato MC, et al. Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis. Mol Med. 2012;18:794&#x2010;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409288</ArticleId><ArticleId IdType="pubmed">22481270</ArticleId></ArticleIdList></Reference><Reference><Citation>Boido M, Piras A, Valsecchi V, et al. Human mesenchymal stromal cell transplantation modulates neuroinflammatory milieu in a mouse model of amyotrophic lateral sclerosis. Cytotherapy. 2014;16:1059&#x2010;1072.</Citation><ArticleIdList><ArticleId IdType="pubmed">24794182</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwala S, Tamplin OJ. Neural crossroads in the hematopoietic stem cell niche. Trends Cell Biol. 2018;28:987&#x2010;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6822267</ArticleId><ArticleId IdType="pubmed">29857963</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh K&#x2010;W, Moon C, Kim HY, et al. Phase I trial of repeated intrathecal autologous bone marrow&#x2010;derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl Med. 2015;4:590&#x2010;597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4449093</ArticleId><ArticleId IdType="pubmed">25934946</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Vescovi A, Cantello R, Gelati M, Vercelli A. Stem cells therapy in ALS. Expert Opin Biol Ther. 2016;16:187&#x2010;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">26558293</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorabi AM, Kiaie N, Barreto GE, Read MI, Tafti HA, Sahebkar A. The therapeutic potential of mesenchymal stem cell&#x2010;derived exosomes in treatment of neurodegenerative diseases. Mol Neurobiol. 2019;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">31197655</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Wu Y. Paracrine molecules of mesenchymal stem cells for hematopoietic stem cell niche. Bone Marrow Res. 2011;2011:1&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196250</ArticleId><ArticleId IdType="pubmed">22046560</ArticleId></ArticleIdList></Reference><Reference><Citation>Caplan AI. Are All Adult Stem Cells The Same? Regen Eng Transl Med. 2015;1:4&#x2010;10.</Citation></Reference><Reference><Citation>Yousefi F, Lavi Arab F, Saeidi K, Amiri H, Mahmoudi M. Various strategies to improve efficacy of stem cell transplantation in multiple sclerosis: Focus on mesenchymal stem cells and neuroprotection. J Neuroimmunol. 2019;328:20&#x2010;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">30557687</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;3:CD001447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldenberg MM. Celecoxib, a selective cyclooxygenase&#x2010;2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin Ther. 1999;21:1497&#x2010;1513.</Citation><ArticleIdList><ArticleId IdType="pubmed">10509845</ArticleId></ArticleIdList></Reference><Reference><Citation>Maciel IS, Silva RB, Morrone FB, Calixto JB, Campos MM. Synergistic effects of celecoxib and bupropion in a model of chronic inflammation&#x2010;related depression in mice. PLoS ONE. 2013;8:e77227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785450</ArticleId><ArticleId IdType="pubmed">24086771</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez&#x2010;Cueto C, Santos&#x2010;Garc&#xed;a I, Garc&#xed;a&#x2010;Toscano L, et al. Neuroprotective effects of the cannabigerol quinone derivative VCE&#x2010;003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis. Biochem Pharmacol. 2018;157:217&#x2010;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">30076846</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne EC, Abbott BM. Recent progress towards an effective treatment of amyotrophic lateral sclerosis using the SOD1 mouse model in a preclinical setting. Eur J Med Chem. 2016;121:918&#x2010;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">27012524</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Sung M, Rutkove SB. Electrophysiologic biomarkers for assessing disease progression and the effect of riluzole in SOD1 G93A ALS mice. PLoS ONE. 2013;8:e65976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675066</ArticleId><ArticleId IdType="pubmed">23762454</ArticleId></ArticleIdList></Reference><Reference><Citation>Pompl PN, Ho L, Bianchi M, McManus T, Qin W, Pasinetti GM. A therapeutic role for cyclooxygenase&#x2010;2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 2003;17:725&#x2010;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">12586733</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa&#x2010;Nunes JP, Cline BH, Ara&#xfa;jo&#x2010;Correia M, et al. Animal models of depression and drug delivery with food as an effective dosing method: evidences from studies with celecoxib and dicholine succinate. Biomed Res Int. 2015;2015:596126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4433645</ArticleId><ArticleId IdType="pubmed">26064929</ArticleId></ArticleIdList></Reference><Reference><Citation>Strekalova T, Wotjak CT, Schachner M. Hippocampal administration of an antibody against the HNK&#x2010;1 carbohydrate impairs memory consolidation in an inhibitory learning task in mice. Mol Cell Neurosci. 2001;17:1102&#x2010;1113.</Citation><ArticleIdList><ArticleId IdType="pubmed">11414798</ArticleId></ArticleIdList></Reference><Reference><Citation>Veniaminova E, Oplatchikova M, Bettendorff L, et al. Prefrontal cortex inflammation and liver pathologies accompany cognitive and motor deficits following Western diet consumption in non&#x2010;obese female mice, 2020;241 10.1016/j.lfs.2019.117163</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2019.117163</ArticleId><ArticleId IdType="pubmed">31837337</ArticleId></ArticleIdList></Reference><Reference><Citation>Donders R, Vanheusden M, Bogie JF, et al. Human Wharton's jelly&#x2010;derived stem cells display immunomodulatory properties and transiently improve rat experimental autoimmune encephalomyelitis. Cell Transplant. 2015;24:2077&#x2010;2098.</Citation><ArticleIdList><ArticleId IdType="pubmed">25310756</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovina MV, Karnaukhov AV, Krasheninnikov ME, et al. Extension of maximal lifespan and high bone marrow chimerism after nonmyeloablative syngeneic transplantation of bone marrow from young to old Mice. Front Genet. 2019;10:310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6473025</ArticleId><ArticleId IdType="pubmed">31031800</ArticleId></ArticleIdList></Reference><Reference><Citation>Howland DS, Liu J, She Y, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant&#x2010;mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA. 2002;99:1604&#x2010;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122237</ArticleId><ArticleId IdType="pubmed">11818550</ArticleId></ArticleIdList></Reference><Reference><Citation>Couch Y, Anthony DC, Dolgov O, et al. Microglial activation, increased TNF and SERT expression in the prefrontal cortex define stress&#x2010;altered behaviour in mice susceptible to anhedonia. Brain Behav Immun. 2013;29:136&#x2010;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">23305936</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorlova A, Pavlov D, Anthony DC, et al. Thiamine and benfotiamine counteract ultrasound&#x2010;induced aggression, normalize AMPA receptor expression and plasticity markers, and reduce oxidative stress in mice. Neuropharmacology. 2019;156:107543.</Citation><ArticleIdList><ArticleId IdType="pubmed">30817932</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda P, Wi&#x15b;niewski J, W&#xf3;jtowicz T, et al. Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging. Expert Opin Ther Targets. 2018;22:833&#x2010;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">30244615</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica R, Paillusson S, Gomez&#x2010;Suaga P, et al. ALS/FTD&#x2010;associated FUS activates GSK&#x2010;3&#x3b2; to disrupt the VAPB&#x2010;PTPIP51 interaction and ER&#x2010;mitochondria associations. EMBO Rep. 2016;179:1326&#x2010;1342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007559</ArticleId><ArticleId IdType="pubmed">27418313</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumitha R, Manjunatha VM, Sabitha RK, et al. Cerebrospinal fluid from patients with sporadic amyotrophic lateral sclerosis induces degeneration of motor neurons derived from human embryonic stem cells. Mol Neurobiol. 2019;56:1014&#x2010;1034.</Citation><ArticleIdList><ArticleId IdType="pubmed">29858777</ArticleId></ArticleIdList></Reference><Reference><Citation>Luca A, Calandra C, Luca M. Molecular bases of Alzheimer's disease and neurodegeneration: the role of neuroglia. Aging Dis. 2018;9:1134&#x2010;1152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6284765</ArticleId><ArticleId IdType="pubmed">30574424</ArticleId></ArticleIdList></Reference><Reference><Citation>Dostert G, Mesure B, Menu P, Velot E. How do mesenchymal stem cells influence or are influenced by microenvironment through extracellular vesicles communication? Front Cell Dev Biol. 2017;5:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5293793</ArticleId><ArticleId IdType="pubmed">28224125</ArticleId></ArticleIdList></Reference><Reference><Citation>Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Res Ther. 2016;7:125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007684</ArticleId><ArticleId IdType="pubmed">27581859</ArticleId></ArticleIdList></Reference><Reference><Citation>Shelkovnikova TA, Robinson HK, Southcombe JA, Ninkina N, Buchman VL. Multistep process of FUS aggregation in the cell cytoplasm involves RNA&#x2010;dependent and RNA&#x2010;independent mechanisms. Hum Mol Genet. 2014;23:5211&#x2010;5226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159159</ArticleId><ArticleId IdType="pubmed">24842888</ArticleId></ArticleIdList></Reference><Reference><Citation>De&#x12d;kin AV, Kovrazhkina EA, Ovchinnikov RK, et al. A mouse model of amyotrophic lateral sclerosis expressing mutant human FUS protein. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(8):62&#x2010;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">25345633</ArticleId></ArticleIdList></Reference><Reference><Citation>Redondo&#x2010;Castro E, Cunningham C, Miller J, et al. Interleukin&#x2010;1 primes human mesenchymal stem cells towards an anti&#x2010;inflammatory and pro&#x2010;trophic phenotype in vitro. Stem Cell Res Ther. 2017;8:79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5393041</ArticleId><ArticleId IdType="pubmed">28412968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kshitiz EDD, Suhail Y, Afzal J, et al. Dynamic secretome of bone marrow&#x2010;derived stromal cells reveals a cardioprotective biochemical cocktail. Proc Natl Acad Sci USA. 2019;116:14374&#x2010;14383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6628676</ArticleId><ArticleId IdType="pubmed">31239339</ArticleId></ArticleIdList></Reference><Reference><Citation>Therrien M, Rouleau GA, Dion PA, Parker JA. FET proteins regulate lifespan and neuronal integrity. Sci Rep. 2016;6:25159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4846834</ArticleId><ArticleId IdType="pubmed">27117089</ArticleId></ArticleIdList></Reference><Reference><Citation>Cline BH, Steinbusch HW, Malin D, et al. The neuronal insulin sensitizer dicholine succinate reduces stress&#x2010;induced depressive traits and memory deficit: possible role of insulin&#x2010;like growth factor 2. BMC Neurosci. 2012;13:110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3564824</ArticleId><ArticleId IdType="pubmed">22989159</ArticleId></ArticleIdList></Reference><Reference><Citation>Sama RR, Ward CL, Kaushansky LJ, et al. FUS/TLS assembles into stress granules and is a prosurvival factor during hyperosmolar stress. J Cell Physiol. 2013;228:2222&#x2010;2231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4000275</ArticleId><ArticleId IdType="pubmed">23625794</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoell JI, Larsson E, Runge S, et al. RNA targets of wild&#x2010;type and mutant FET family proteins. Nat Struct Mol Biol. 2011;18:1428&#x2010;1431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230689</ArticleId><ArticleId IdType="pubmed">22081015</ArticleId></ArticleIdList></Reference><Reference><Citation>Crivello M, Hogg MC, Jirstr&#xf6;m E, et al. Vascular regression precedes motor neuron 1 loss in the FUS (1&#x2013;359) ALS mouse model. Dis Model Mech. 2019;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6737946</ArticleId><ArticleId IdType="pubmed">31383794</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz&#x2010;L&#xf3;pez FJ, Guardiola J, Izura V, et al. Breathing pattern in a phase I clinical trial of intraspinal injection of autologous bone marrow mononuclear cells in patients with amyotrophic lateral sclerosis. Respir Physiol Neurobiol. 2016;221:54&#x2010;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">26593639</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>